title: Influence of the luteinizing hormone-releasing hormone agonist, deslorelin, on patterns of estradiol-17 beta and luteinizing hormone secretion, ovarian follicular responses to superstimulation with follicle-stimulating hormone, and recovery and in vitro development of oocytes in heifer calves.
abstract: The objective of this study was to determine the effects of inducing pituitary desensitization by treatment with an LHRH agonist (deslorelin) on reproductive hormone secretion and ovarian follicular status in heifer calves, before and during stimulation with FSH. The recovery and in vitro development of oocytes was also investigated. Brahman (Bos indicus) calves, 6 mo old, received either no treatment from Day 0 to Day 8 and injections of FSH on Days 9, 10, and 11 (controls, n = 10), or bioimplants of deslorelin on Day 0 and injections of FSH on Days 9, 10, and 11 (deslorelin calves, n = 10). Ovarian follicular characteristics were determined on Days -2, 0, and 8 by ultrasonography; follicle sizes (2-4 mm, 5-7 mm, 8-9 mm, or > or = 10 mm) were recorded. Ovaries were removed surgically on Day 12, surface follicle numbers and sizes were recorded, and oocytes were aspirated, graded (A-grade, B-grade, denuded, atretic), and prepared for in vitro fertilization and culture. Blood samples were taken throughout the experiment to monitor plasma concentrations of LH, estradiol-17 beta (estradiol) and progesterone. Treatment with deslorelin desensitized the pituitary in heifer calves and altered patterns of LH and estradiol secretion. There were no apparent consistent effects of deslorelin treatment on follicle numbers and growth. A higher number of combined A-grade and B-grade oocytes were obtained from heifers treated with deslorelin, which, in turn, resulted in twice the number of blastocysts. Treatment with an LHRH agonist provides a model for studying the hormonal requirements for follicle growth and in vivo oocyte maturation in heifer calves.
authors.affiliation: CSIRO Tropical Agriculture, Central Queensland University, Rockhampton, Queensland, Australia.
authors.forename: L J
authors.initials: LJ
authors.lastname: Maclellan
authors.forename: E G
authors.initials: EG
authors.lastname: Bergfeld
authors.forename: C R
authors.initials: CR
authors.lastname: Earl
authors.forename: L A
authors.initials: LA
authors.lastname: Fitzpatrick
authors.forename: W J
authors.initials: WJ
authors.lastname: Aspden
authors.forename: J E
authors.initials: JE
authors.lastname: Kinder
authors.forename: J
authors.initials: J
authors.lastname: Walsh
authors.forename: T E
authors.initials: TE
authors.lastname: Trigg
authors.forename: M J
authors.initials: MJ
authors.lastname: D'Occhio
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002417:Cattle; D004334:Drug Administration Schedule; D004343:Drug Implants; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000097:blood / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists* / Q000031:analogs & derivatives* / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010052:Ovariectomy; D011374:Progesterone / Q000097:blood / Q000378:metabolism; D012016:Reference Values; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives
chemical_list: D004343:Drug Implants; D004791:Enzyme Inhibitors; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C066438:deslorelin